Published in J Clin Invest on March 01, 1995
Regulation of the fission yeast transcription factor Pap1 by oxidative stress: requirement for the nuclear export factor Crm1 (Exportin) and the stress-activated MAP kinase Sty1/Spc1. Genes Dev (1998) 3.27
Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob Agents Chemother (1997) 1.19
Regulation of Cisplatin cytotoxicity by cu influx transporters. Met Based Drugs (2011) 1.00
Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer (2007) 0.93
Depletion of the ER chaperone ENPL-1 sensitizes C. elegans to the anticancer drug cisplatin. Worm (2013) 0.78
Utilization of arsenic trioxide as a treatment of cisplatin-resistant non-small cell lung cancer PC-9/CDDP and PC-14/CDDP cells. Oncol Lett (2015) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Drugs five years later. Cisplatin. Ann Intern Med (1984) 3.69
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
COT1, a gene involved in cobalt accumulation in Saccharomyces cerevisiae. Mol Cell Biol (1992) 2.62
Identification of a gene conferring resistance to zinc and cadmium ions in the yeast Saccharomyces cerevisiae. Mol Gen Genet (1989) 2.46
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Resistance to cadmium, cobalt, zinc, and nickel in microbes. Plasmid (1992) 2.38
Heavy metal tolerance in the fission yeast requires an ATP-binding cassette-type vacuolar membrane transporter. EMBO J (1992) 2.19
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Metalloregulated expression of the ars operon. J Biol Chem (1993) 1.98
CzcR and CzcD, gene products affecting regulation of resistance to cobalt, zinc, and cadmium (czc system) in Alcaligenes eutrophus. J Bacteriol (1992) 1.96
Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry (1983) 1.96
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
Heavy metal resistance: a new role for P-glycoproteins in Leishmania. J Biol Chem (1991) 1.55
Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol (1981) 1.54
Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol (1972) 1.52
Plasmid-encoded resistance to arsenic and antimony. Plasmid (1992) 1.46
A plasmid-encoded arsenite pump produces arsenite resistance in Escherichia coli. Biochem Biophys Res Commun (1984) 1.34
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Arsenic efflux governed by the arsenic resistance determinant of Staphylococcus aureus plasmid pI258. J Bacteriol (1993) 1.14
Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer (1989) 1.08
Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res (1987) 1.02
Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res (1991) 1.02
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans R Soc Trop Med Hyg (1990) 0.99
Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer (1991) 0.98
Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Res (1986) 0.97
Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Lett (1987) 0.96
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest (1993) 0.93
Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines. Br J Cancer (1991) 0.93
Characteristics of multidrug resistance in Plasmodium and Leishmania: detection of P-glycoprotein-like components. Am J Trop Med Hyg (1991) 0.89
Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res (1989) 0.88
Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cis-diamminedichloroplatinum(II) in human NHIK 3025 cells. Cancer Res (1989) 0.84
Characterization of a phosphate transport system in human fibroblast lysosomes. J Biol Chem (1991) 0.82
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The lethal effect of mebendazole on secondary Echinococcus granulosus, cysticerci of Taenia pisiformis and tetrathyridia of Mesocestoides corti. Parasitology (1975) 2.97
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Importance of state of methylation of oriC GATC sites in initiation of DNA replication in Escherichia coli. EMBO J (1985) 1.77
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Vaccination against hydatidosis using a defined recombinant antigen. Parasite Immunol (1996) 1.63
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Vaccination against ovine cysticercosis using a defined recombinant antigen. Nature (1989) 1.46
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Circulating immunoglobulin complexes in Wegener's granulomatosis. Am J Med (1976) 1.43
Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. Int J Parasitol (1999) 1.40
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
Neurological complications of ankle arthroscopy. Arthroscopy (1996) 1.38
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
In vitro replication directed by a cloned adenovirus origin. Gene (1983) 1.24
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Parastrongyloides trichosuri, a nematode parasite of mammals that is uniquely suited to genetic analysis. Int J Parasitol (2006) 1.17
Vaccination against cysticercosis and hydatid disease. Parasitol Today (2000) 1.17
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Totally implantable system for peritoneal access. J Clin Oncol (1984) 1.15
Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene (2001) 1.15
The MHC and non-random mating in a captive population of Chinook salmon. Heredity (Edinb) (2008) 1.14
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
Transmission dynamics and control options for Echinococcus granulosus. Parasitology (2003) 1.13
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol (1994) 1.11
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol (1994) 1.10
Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol (1999) 1.08
Quantitative genetic and translocation experiments reveal genotype-by-environment effects on juvenile life-history traits in two populations of Chinook salmon (Oncorhynchus tshawytscha). J Evol Biol (2010) 1.07
Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer (1975) 1.07
Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. Br J Cancer (1996) 1.06
Molecular and genetic characterisation of the host-protective oncosphere antigens of taeniid cestode parasites. Int J Parasitol (2003) 1.04
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer (1999) 1.03
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). J Biol Chem (1998) 1.03
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest (1990) 1.03
Protection against hydatid disease induced with the EG95 vaccine is associated with conformational epitopes. Vaccine (2000) 1.02
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
Possible antigenic similarity between pulmonary carcinoma and cysts of Echinococcus granulosus. Br Med J (1979) 1.01
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
Epitope specificities and antibody responses to the EG95 hydatid vaccine. Parasite Immunol (1998) 1.00
Letter: Mebendazole and hydatid cysts. Lancet (1974) 1.00
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer (2004) 1.00
Transcriptional differences between triploid and diploid Chinook salmon (Oncorhynchus tshawytscha) during live Vibrio anguillarum challenge. Heredity (Edinb) (2009) 0.99
Cell interactions in adoptive immune rejection of a syngeneic tumor. Int J Cancer (1974) 0.99
Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. Br J Cancer (1994) 0.98
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res (1993) 0.98
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res (2001) 0.98
Hybridization dynamics between sympatric species of trout: loss of reproductive isolation. J Evol Biol (2005) 0.98
Challenges for diagnosis and control of cystic hydatid disease. Acta Trop (2012) 0.97
Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev (2000) 0.97
Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact (1988) 0.97
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res (2001) 0.97
The migration of oncospheres of Taenia pisiformis, T. serialis and Echinococcus granulosus within the intermediate host. Int J Parasitol (1971) 0.96
Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res (1981) 0.95
Sensitive genetic biomarkers for determining apoptosis in the brown bullhead (Ameiurus nebulosus). Gene (2004) 0.94
Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res (1980) 0.94
Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum (1980) 0.93
Characterisation and expression of an Hsp70 gene from Parastrongyloides trichosuri. Int J Parasitol (2006) 0.93
Utilization of stomach content DNA to determine diet diversity in piscivorous fishes. J Fish Biol (2011) 0.93
Cellular immunity in mice with simian virus 40-induced mKSA tumors: comparison of three assays of tumor immunity. J Natl Cancer Inst (1974) 0.93
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol (1984) 0.93
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest (1993) 0.93
Resistance to Taenia pisiformis larvae in rabbits. II. Temporal relationships and the development phase affected. Int J Parasitol (1973) 0.93
Identification and cDNA cloning of two novel low molecular weight host-protective antigens from Taenia ovis oncospheres. Int J Parasitol (1996) 0.93
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol (1993) 0.92
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol (1985) 0.92
Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer (2000) 0.92
Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer (1997) 0.92
Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res (1992) 0.92
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer (1998) 0.91
Ultrastructure of oncosphere and early stages of metacestode development of Echinococcus granulosus. Int J Parasitol (1994) 0.91
Mutational mapping of a cloned adenovirus origin. Gene (1983) 0.91
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br J Cancer (1997) 0.91
The cellular pharmacology of oxaliplatin resistance. Eur J Cancer (2002) 0.91
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer (1994) 0.91
Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res (1990) 0.91
all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res (1997) 0.90
High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol (1985) 0.90